Guangzhou Yunyuan Biotech Co., Ltd.

Academy of Military Medical Sciences

Hefei Tairui Biotechnology Co., Ltd.

Cheng Cao

Michael Rynkiewicz

Yanwen Jin

David Weaver

Song Li

Wu Zhong

David T Weaver

Ruiyuan Cao

Ting Gao

Leike Zhang

Gengfu Xiao

Zhihong Hu

Manli Wang

The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection. 

Use of Favipiravir in treatment of coronavirus infection

A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.

Humanized anti-EGFR antibody L4-H3 and coding gene thereof

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13&#xd7;10mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

Anti-epidermal growth factor receptor antibodies and uses thereof

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09&#xd7;10mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

Growing community of inventors

Beijing, China

Cheng Cao